MARKET

NTRP

NTRP

Neurotrope
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.180
0.000
0.00%
After Hours: 1.200 +0.02 +1.69% 16:20 12/06 EST
OPEN
1.180
PREV CLOSE
1.180
HIGH
1.290
LOW
1.020
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
0.6300
MARKET CAP
15.42M
P/E (TTM)
-0.8387
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NTRP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NTRP News

  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.10/10 11:31
  • 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.10/09 11:54
  • 30 Stocks Moving In Tuesday's Mid-Day Session
  • Benzinga.10/08 16:30
  • Mid-Day Market Update: Qiagen Falls Following Q3 Sales Warning; Asure Software Shares Surge
  • Benzinga.10/08 16:01

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About NTRP

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
More

Webull offers Neurotrope Inc (NTRP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.